Latest / DDReg Knowledge Capsule / Dietary Supplement Registration in Brazil vs. Mexico ANVISA and COFEPRIS Market Entry Pathways

Transcript

Dietary Supplement Registration in Brazil vs. Mexico ANVISA and COFEPRIS Market Entry Pathways · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the D.D. Reg Knowledge Capsule. Imagine just spending
• 0:05
  Speaker 1: half a million dollars to formulate, manufacture, and then ship
• 0:09
  Speaker 1: a highly anticipated premium dietary supplement. Oh, wow.
• 0:12
  Speaker 2: Yeah, that is a massive upfront investment. Right.
• 0:15
  Speaker 1: I mean, you have done all the demographic research. The
• 0:18
  Speaker 1: regional demand is absolutely off the charts. And your cargo
• 0:21
  Speaker 1: ship finally arrives at the port in Veracruz, Mexico.
• 0:25
  Speaker 2: Okay, so you are thinking you are ready to launch. Exactly.
• 0:28
  Speaker 1: But then... The product just sits there in a customs warehouse.
• 0:31
  Speaker 1: I mean, days turn into weeks. You are bleeding capital.
• 0:35
  Speaker 1: And the authorities absolutely refuse to clear the shipment.
• 0:38
  Speaker 2: And let me guess, it is over a label issue.
• 0:41
  Speaker 1: You got it. Because, well, a single translated word on
• 0:45
  Speaker 1: your Spanish label implies your product, quotes and quotes, cures
• 0:49
  Speaker 1: joint pain instead of just saying it supports joint health.
• 0:53
  Speaker 2: Yeah, that is a brutally common scenario, unfortunately.
• 0:56
  Speaker 1: We are thrilled to have you here for this custom-tailored
• 0:59
  Speaker 1: deep dive because today we are going to make sure
• 1:03
  Speaker 1: your product never ends up trapped in that warehouse. We
• 1:06
  Speaker 1: are looking at a really comprehensive October 2026 industry briefing
• 1:10
  Speaker 1: from DD Reg Pharma.
• 1:12
  Speaker 2: Yes, and this briefing focuses specifically on dietary supplement registration
• 1:16
  Speaker 2: in Brazil versus Mexico, which is, you know, a huge
• 1:19
  Speaker 2: topic right now.
• 1:20
  Speaker 1: It really is. And our goal here, our mission for
• 1:24
  Speaker 1: you today, is to completely shatter this very expensive myth
• 1:29
  Speaker 1: that still circulates in corporate boardrooms.
• 1:31
  Speaker 2: Right. This idea that Latin America is just a single
• 1:34
  Speaker 2: unified market with a one size fits all set of rules.
• 1:38
  Speaker 1: You hear it all the time from executives trying to
• 1:41
  Speaker 1: scale quickly. They look at a map. They see the
• 1:45
  Speaker 1: two massive economic powerhouses of Latin America. And they just
• 1:49
  Speaker 1: assume that a unified regional commercial strategy naturally translates into
• 1:53
  Speaker 1: a unified regional regulatory pathway.
• 1:56
  Speaker 2: Yeah, they really do. And we are going to provide
• 1:58
  Speaker 2: you with a strategic shortcut to mastering the fundamentally different
• 2:02
  Speaker 2: regulatory philosophies of Brazil's Anvisa and Mexico's Cafapress.
• 2:07
  Speaker 1: And just to set the stage for you, the core
• 2:10
  Speaker 1: contradiction we are dealing with here is wild.
• 2:13
  Speaker 2: It really is. I mean, on one side of the continent,
• 2:15
  Speaker 2: Brazil demands mandatory notification for every single supplement under a
• 2:20
  Speaker 2: specific food regularization framework. Right.
• 2:23
  Speaker 1: But then on the other side, Mexico does not even
• 2:25
  Speaker 1: require a conventional product registration for supplements at all.
• 2:28
  Speaker 2: No registration at all. And yet somehow both of these
• 2:31
  Speaker 2: systems are just total regulatory minefields.
• 2:35
  Speaker 1: OK, let's unpack this. The boardroom trap we just mentioned
• 2:40
  Speaker 1: really happens because companies completely confuse translation with localization.
• 2:45
  Speaker 2: Exactly. They assume that, well, if they have a successful
• 2:49
  Speaker 2: global formula, they can just translate the label into Portuguese
• 2:52
  Speaker 2: for Brazil and Spanish for Mexico.
• 2:55
  Speaker 1: Yeah, like just hand the dossier over to a local
• 2:57
  Speaker 1: importer and expect a green light.
• 2:59
  Speaker 2: But the philosophical difference at play between these two nations,
• 3:02
  Speaker 2: it alters the very DNA of how you must approach
• 3:05
  Speaker 2: market entry.
• 3:06
  Speaker 1: Because Brazil operates a system that is fundamentally, quote unquote, notification-led, right,
• 3:11
  Speaker 1: governed by their health authority on visa.
• 3:14
  Speaker 2: Right. Whereas Mexico, conversely, operates under COFAPRIS, with a system
• 3:19
  Speaker 2: that is heavily compliance and control-led. And this is specifically
• 3:23
  Speaker 2: because they lack that conventional sanitary product registration for this category.
• 3:27
  Speaker 1: That sounds like assuming that just because two countries both
• 3:30
  Speaker 1: have highways, the traffic laws are identical.
• 3:32
  Speaker 2: That is a perfect way to put it, actually.
• 3:34
  Speaker 1: I mean, you can't just take a global formula, slap
• 3:38
  Speaker 1: a translated label on it, hand it to an importer
• 3:40
  Speaker 1: and expect a green light. You wouldn't drive a commercial
• 3:43
  Speaker 1: truck across a border without checking if the weight limits
• 3:46
  Speaker 1: completely change the moment you cross the line.
• 3:48
  Speaker 2: Absolutely not. A highly accurate comparison. And getting that fundamental
• 3:52
  Speaker 2: philosophical framework wrong up front, well, it is the root
• 3:56
  Speaker 2: cause of disaster down the line.
• 3:58
  Speaker 1: Right. Because if you assume the rules are mirrored, what happens?
• 4:02
  Speaker 2: You will inevitably face forced, costly reformulations. I mean, you
• 4:06
  Speaker 2: will be tearing up perfectly good packaging for localized relabeling.
• 4:10
  Speaker 1: And you will suffer those indefinite customs delays we talked about.
• 4:13
  Speaker 2: Yeah, exactly. The regulatory pathways are just so distinct that
• 4:17
  Speaker 2: an administrative approach that guarantees a successful launch in Sao
• 4:20
  Speaker 2: Paulo will almost certainly guarantee a shipment seizure in Mexico City.
• 4:25
  Speaker 1: OK, let's dig into the actual machinery of Brazil first,
• 4:27
  Speaker 1: because the recent updates there are massive.
• 4:31
  Speaker 2: They really are. It is a completely new landscape.
• 4:34
  Speaker 1: So Brazil regulates dietary supplements through their broader food framework.
• 4:39
  Speaker 1: And the DD Reg Briefing highlights two very specific recently
• 4:43
  Speaker 1: enforced regulatory updates, RDC 843-2024 and IN 281-2024.
• 4:51
  Speaker 2: And the context here is critical for anyone listening who
• 4:53
  Speaker 2: might be relying on, say, slightly older market intelligence.
• 4:57
  Speaker 1: Right, because these frameworks were essentially a massive systemic overhaul.
• 5:02
  Speaker 1: They consolidated dozens of fragmented older rules into a unified,
• 5:07
  Speaker 1: much stricter post-market net.
• 5:09
  Speaker 2: Yes. And as of September 2026, the transition deadline for
• 5:13
  Speaker 2: companies to comply with this new system reached its absolute
• 5:16
  Speaker 2: final stage.
• 5:17
  Speaker 1: So if you are operating on a playbook from 2023,
• 5:20
  Speaker 1: you are not just slightly out of date. You are
• 5:23
  Speaker 1: legally invisible in Brazil.
• 5:25
  Speaker 2: Oh, you are driving off a cliff. The transition period
• 5:28
  Speaker 2: is over, meaning Anvisa is now fully enforcing the RDC
• 5:31
  Speaker 2: 843 framework.
• 5:33
  Speaker 1: So under this current system, dietary supplements are subject to
• 5:37
  Speaker 1: mandatory notification before you can market them.
• 5:40
  Speaker 2: Right. But the mechanism of how that notification is processed
• 5:43
  Speaker 2: is where companies completely miscalculate their risk profile.
• 5:47
  Speaker 1: The source says the notification to Anvisa is, quote unquote,
• 5:50
  Speaker 1: automatic when requirements are met with no substantive pre-market valuation.
• 5:56
  Speaker 1: Does that mean Brazil is a regulatory free-for-all?
• 5:59
  Speaker 2: Oh, absolutely not. I firmly have to correct that assumption.
• 6:03
  Speaker 2: A layman might read that and think it is easy,
• 6:05
  Speaker 2: but it is actually a radical shift in the burden
• 6:07
  Speaker 2: of proof.
• 6:08
  Speaker 1: OK, break that down for us. What is the actual
• 6:11
  Speaker 1: catch to this automatic entry?
• 6:13
  Speaker 2: Well, in a traditional pre-market approval system like you see
• 6:16
  Speaker 2: with certain categories in Europe or even pharmaceutical tracks globally,
• 6:19
  Speaker 2: the government does the heavy lifting. Right.
• 6:21
  Speaker 1: They evaluate your clinical data, your safety profiles, all your
• 6:24
  Speaker 1: stability studies before you ever launch.
• 6:27
  Speaker 2: Exactly. It takes years, but once you have the approval,
• 6:30
  Speaker 2: you have a shield. But Brazil's current automatic notification system
• 6:34
  Speaker 2: strips away that pre-market shield entirely.
• 6:37
  Speaker 1: So Anvisa is essentially saying, we will let you get
• 6:40
  Speaker 1: to market with unprecedented speed, but you are entirely responsible
• 6:44
  Speaker 1: for pristine compliance from day one.
• 6:45
  Speaker 2: Yes. And we will be actively hunting for violations post-launch.
• 6:50
  Speaker 2: So the speed of pre-market entry directly creates an immense
• 6:54
  Speaker 2: post-market vulnerability. Wow.
• 6:56
  Speaker 1: So you aren't avoiding the intense scrutiny anymore. You are
• 6:59
  Speaker 1: just delaying it until your product is already on the shelves,
• 7:01
  Speaker 1: which is arguably much more dangerous.
• 7:05
  Speaker 2: Far more dangerous. I mean, the financial exposure is exponential
• 7:09
  Speaker 2: at that point. If we want to see exactly how
• 7:11
  Speaker 2: Anvisa wields this post-market power, we just have to look
• 7:13
  Speaker 2: at the turmeric crackdown that happened in September 2026.
• 7:16
  Speaker 1: Oh, right. The turmeric situation. Because turmeric and curcumin-based supplements
• 7:21
  Speaker 1: were just booming at the time.
• 7:23
  Speaker 2: They were everywhere. Everywhere. Companies filed their automatic notifications, hit
• 7:27
  Speaker 2: the market, and felt completely secure. But Envisa wasn't ignoring them.
• 7:31
  Speaker 1: They were quietly aggregating post-market surveillance data, right? And looking
• 7:36
  Speaker 1: at real-world clinical evidence.
• 7:38
  Speaker 2: Precisely. And they realized that certain high concentrations of curcuminoids
• 7:42
  Speaker 2: were triggering adverse events, specifically hepatotoxicity, which is liver damage.
• 7:48
  Speaker 1: And because Brazil's system is notification-led, And Visa didn't have
• 7:51
  Speaker 1: to go through a years-long legislative process to recall specific brands.
• 7:56
  Speaker 2: Exactly. They simply utilized the agile nature of IN-28-2024 to
• 8:01
  Speaker 2: abruptly update the normative limits. They imposed strict new caps
• 8:05
  Speaker 2: on curcuminoid concentrations and mandated severe new warning labels regarding
• 8:09
  Speaker 2: liver health.
• 8:10
  Speaker 1: Literally overnight. I mean, thousands of automatically notified products that
• 8:14
  Speaker 1: were perfectly legal on a Monday became entirely noncompliant by Tuesday. Yep.
• 8:21
  Speaker 2: If you were treating that initial automatic notification as a permanent,
• 8:24
  Speaker 2: unassailable green light, your entire inventory was suddenly illegal to sell.
• 8:29
  Speaker 1: It's like they operate like a highly automated toll booth.
• 8:32
  Speaker 1: You zoom through the electronic toll without stopping, feeling great
• 8:35
  Speaker 1: about your speed. Right.
• 8:37
  Speaker 2: But there's a massive, highly coordinated fleet of highway patrol
• 8:40
  Speaker 2: cars waiting just out of sight.
• 8:42
  Speaker 1: Yes. And the second you hit the open road, they
• 8:44
  Speaker 1: are running your plates, checking your cargo weight, measuring your emissions.
• 8:48
  Speaker 1: And if the speed limit changes while you are driving... Well,
• 8:50
  Speaker 1: you are expected to already be breaking.
• 8:53
  Speaker 2: And the penalties for failing to break are severe. To
• 8:56
  Speaker 2: survive in Brazil, a company must maintain an ongoing, highly
• 8:59
  Speaker 2: active compliance team.
• 9:01
  Speaker 1: Because you have to constantly monitor your formulation against Anvisa's
• 9:04
  Speaker 1: dynamic positive lists for permuted claims and maximum use levels.
• 9:09
  Speaker 2: Exactly. The notification is literally just the starting line. It
• 9:13
  Speaker 2: offers zero protection if the regulatory winds shift.
• 9:17
  Speaker 1: OK, so if Brazil's trap is what happens after you launch,
• 9:21
  Speaker 1: Mexico's trap seems to be the invisible wall preventing you
• 9:24
  Speaker 1: from launching in the first place.
• 9:26
  Speaker 2: Yes. Let's shift our focus to COFEPRIS, Mexico's federal health authority.
• 9:31
  Speaker 1: We mentioned earlier that dietary supplements in Mexico generally do
• 9:34
  Speaker 1: not require a formal sanitary product registration. Right.
• 9:38
  Speaker 2: To enter the market, you must prove your product meets
• 9:40
  Speaker 2: the legal definition of a supplement.
• 9:42
  Speaker 1: Which is something explicitly intended to increase, complement, or supplement
• 9:46
  Speaker 1: total dietary intake. And then you have to comply with
• 9:49
  Speaker 1: localized controls.
• 9:51
  Speaker 2: Which creates a really fascinating paradox for manufacturers. Strict control
• 9:56
  Speaker 2: without formal registration.
• 9:58
  Speaker 1: Here's where it gets really interesting. as a thought experiment.
• 10:01
  Speaker 1: If I am a manufacturer and I don't have to
• 10:04
  Speaker 1: register the product, aren't I flying blind?
• 10:07
  Speaker 2: You would think so, yeah.
• 10:08
  Speaker 1: I mean, how do I even know if my product
• 10:10
  Speaker 1: is legally a supplement in Mexico before I invest millions
• 10:13
  Speaker 1: in a launch?
• 10:14
  Speaker 2: Well, you utilize the primary tool Cofepris offers to mitigate
• 10:18
  Speaker 2: that blindness. It is called the classification consultation.
• 10:21
  Speaker 1: Okay. What exactly is that?
• 10:24
  Speaker 2: Because Mexico lacks a formal gatekeeper issuing a definitive approved
• 10:28
  Speaker 2: stamp for supplements, you have to navigate this invisible matrix
• 10:31
  Speaker 2: of controls. The classification consultation allows a company to proactively
• 10:36
  Speaker 2: submit their product's composition, intended use, and labeling to the authority.
• 10:41
  Speaker 1: So Cafepris reviews it and provides a technical opinion on
• 10:44
  Speaker 1: whether your formulation and presentation legitimately qualify as a dietary supplement.
• 10:49
  Speaker 2: Right. But the briefing makes a very careful distinction here.
• 10:52
  Speaker 2: A technical opinion is not a sanitary authorization. Got it.
• 10:56
  Speaker 1: So it sounds like a pre-screening that confirms you are
• 10:59
  Speaker 1: legally allowed to step onto the playing field, but it
• 11:02
  Speaker 1: doesn't mean you have won the game.
• 11:04
  Speaker 2: Exactly. Or even that you are fully allowed to start
• 11:06
  Speaker 2: selling it. That distinction is the backbone of Mexican regulatory strategy.
• 11:11
  Speaker 1: The technical opinion simply confirms you are subject to supplement
• 11:14
  Speaker 1: regulations rather than pharmaceutical regulations.
• 11:17
  Speaker 2: Yep. And once you have that confirmation, the actual matrix
• 11:21
  Speaker 2: of controls activates. You are legally required to file an
• 11:25
  Speaker 2: aviso de funcionamiento.
• 11:27
  Speaker 1: Which is a mandatory establishment notice, right?
• 11:30
  Speaker 2: Yes. It essentially tells COFEPRIS, hey, we have a local
• 11:33
  Speaker 2: operator handling this specific class of goods. And if you
• 11:36
  Speaker 2: are importing the product, which most international companies are, you
• 11:40
  Speaker 2: immediately run into the permiso sanitario previo de importacion, or PSPI.
• 11:45
  Speaker 1: The pre-import sanitary permit. This is where Mexico's true control
• 11:50
  Speaker 1: mechanism lies. And a major part of securing that PSPI,
• 11:54
  Speaker 1: according to the briefing, is an intense, almost microscopic scrutiny
• 11:59
  Speaker 1: over advertising and labeling claims.
• 12:01
  Speaker 2: Oh, absolutely microscopic.
• 12:03
  Speaker 1: Why is COFEPRIS so hypervigilant about the specific phrasing of
• 12:07
  Speaker 1: marketing claims, perhaps even more so than the raw ingredients themselves?
• 12:11
  Speaker 2: Well, we have to look at the broader public health
• 12:13
  Speaker 2: mandate of COFEPRIS to understand their behavior. Because dietary supplements
• 12:17
  Speaker 2: bypass the rigorous, multi-phase clinical trials required for pharmaceuticals, cofepris
• 12:23
  Speaker 2: views them as an area of high risk for consumer exploitation. Right.
• 12:27
  Speaker 1: They are fiercely protective of the line between augmenting a
• 12:30
  Speaker 1: diet and treating a disease.
• 12:32
  Speaker 2: Exactly. They heavily police claims to ensure they are not therapeutic, preventative,
• 12:37
  Speaker 2: or curative.
• 12:38
  Speaker 1: So if your marketing suggests your concentrated vitamin C powder, quote-unquote,
• 12:43
  Speaker 1: cures the common cold.
• 12:44
  Speaker 2: or your herbal.
• 12:45
  Speaker 1: Blend treats insomnia, Cofepris will immediately reclassify you.
• 12:49
  Speaker 2: Yes. They view you as an unregistered illegal medicine rather
• 12:53
  Speaker 2: than a non-compliant supplement, which triggers an immediate shutdown.
• 12:56
  Speaker 1: Wow. They police the promises you make on the box
• 13:00
  Speaker 1: just as strictly as the chemical compounds inside the bottle.
• 13:02
  Speaker 2: Absolutely.
• 13:03
  Speaker 1: Let's talk about the physical manifestation of these abstract legal frameworks.
• 13:08
  Speaker 1: Because Ultimately, these regulations dictate the physical reality of the
• 13:12
  Speaker 1: product in the consumer's hands.
• 13:13
  Speaker 2: Yes, and the labeling requirements alone are a perfect case
• 13:16
  Speaker 2: study in why a single global artwork file will absolutely
• 13:20
  Speaker 2: fail in Latin America.
• 13:22
  Speaker 1: Let's contrast the physical demands. In Brazil, your label must
• 13:25
  Speaker 1: obviously be in Portuguese.
• 13:27
  Speaker 2: Right, but the RDC 843 framework demands highly specific health
• 13:31
  Speaker 2: warnings based on your ingredients.
• 13:33
  Speaker 1: And it mandates the mandatory prominent display of the phrase
• 13:37
  Speaker 1: suplemento alimentar, right alongside the product's presentation form.
• 13:42
  Speaker 2: You cannot hide the classification. Anvisa wants the consumer to
• 13:46
  Speaker 2: know instantly and unequivocally that this is a dietary supplement
• 13:50
  Speaker 2: subject to supplement rules.
• 13:52
  Speaker 1: Now, contrast that with Mexico, where the label must be
• 13:55
  Speaker 1: in Spanish. But the overarching design philosophy is entirely defensive.
• 14:00
  Speaker 2: Defensive is the perfect word. You are formatting the label
• 14:04
  Speaker 2: specifically to prevent any sort of medicinal positioning. Right.
• 14:09
  Speaker 1: You are mandated to include exact lot numbers, specific expiry
• 14:13
  Speaker 1: date formats, rigorous allergen disclosures, and exact manufacturer details.
• 14:18
  Speaker 2: All framed using language that deliberately avoids crossing the therapeutic line.
• 14:23
  Speaker 2: You cannot assume that just because your Spanish label meets
• 14:26
  Speaker 2: general food requirements in Mexico, it satisfies the supplement-specific framework.
• 14:31
  Speaker 1: So just direct translating the label is like wearing a
• 14:34
  Speaker 1: tuxedo to a beach wedding in Mexico. Technically, you're dressed...
• 14:38
  Speaker 1: but you are entirely violating the local environment.
• 14:41
  Speaker 2: Oh, that is a great way to put it. The
• 14:43
  Speaker 2: environmental context is everything. You might have technically translated every
• 14:48
  Speaker 2: word accurately, but if you haven't adapted the tone and
• 14:51
  Speaker 2: formatting to the specific local environment, authorities will spot the
• 14:55
  Speaker 2: anomaly instantly.
• 14:56
  Speaker 1: And if your label triggers an anomaly during the import process,
• 14:59
  Speaker 1: you aren't just facing a fine. You are facing a
• 15:02
  Speaker 1: hard border stop.
• 15:04
  Speaker 2: Which brings us to the logistics of importing, where the
• 15:07
  Speaker 2: regulatory theory becomes a harsh physical reality. This is a
• 15:10
  Speaker 2: major friction point for companies.
• 15:12
  Speaker 1: It is. Shipping the physical boxes across international borders. The
• 15:17
  Speaker 1: standard corporate instinct is to view importing as purely a
• 15:20
  Speaker 1: supply chain issue. Right.
• 15:21
  Speaker 2: You hire a global freight forwarder, hand them the commercial invoice,
• 15:25
  Speaker 2: and expect them to handle the customs clearance.
• 15:27
  Speaker 1: But that instinct is a fatal error in Latin America.
• 15:30
  Speaker 1: The critical mind shift executives must make is understanding that
• 15:34
  Speaker 1: import compliance is a core regulatory work stream, not just logistics.
• 15:39
  Speaker 2: Exactly. It is a regulatory gateway.
• 15:42
  Speaker 1: How does the mechanical execution of that regulatory import process
• 15:46
  Speaker 1: differ between the two authorities?
• 15:48
  Speaker 2: Well, in Brazil, the entire system hinges on identifying and
• 15:51
  Speaker 2: appointing a responsible Brazilian entity.
• 15:54
  Speaker 1: This could be your own local subsidiary or a partnered importer, right?
• 15:58
  Speaker 2: Yes, but they must hold the applicable sanitary licensing from
• 16:01
  Speaker 2: Anvisa to handle supplements. They are the ones legally on
• 16:05
  Speaker 2: the hook for the product's compliance.
• 16:07
  Speaker 1: Therefore, your Anvisa notification status must be active, your Portuguese
• 16:11
  Speaker 1: labeling must be perfectly applied, and your localized formulations must
• 16:14
  Speaker 1: be pristine before that shipment ever leaves your home port.
• 16:18
  Speaker 2: Because if the documentation doesn't perfectly align with the local
• 16:21
  Speaker 2: entity's licenses, it's rejected, period.
• 16:24
  Speaker 1: And Mexico flips that model entirely. Instead of relying purely
• 16:27
  Speaker 1: on the local entity's license, the border itself acts as
• 16:31
  Speaker 1: an active regulatory checkpoint through the PSPI we discussed.
• 16:34
  Speaker 2: Yes, the PSPI is not just a bill of lading.
• 16:38
  Speaker 2: It is a proactive regulatory review.
• 16:40
  Speaker 1: So when you apply for that pre-import permit, Cofepris is
• 16:44
  Speaker 1: actively reviewing your product information, your Spanish labeling, your ingredient breakdowns.
• 16:49
  Speaker 2: And you're supporting documents like certificates of free sale from
• 16:52
  Speaker 2: your country of origin as a prerequisite for border clearances.
• 16:56
  Speaker 2: In Mexico, customs officials are essentially acting as an extension
• 17:00
  Speaker 2: of the health authority. Wow.
• 17:02
  Speaker 1: If your documentation hints at medicinal claims or your classification
• 17:06
  Speaker 1: consultation isn't airtight, the PSPI is denied and the product
• 17:11
  Speaker 1: never enters the country.
• 17:12
  Speaker 2: Exactly. Okay.
• 17:14
  Speaker 1: So we have established that the regional shortcut is a
• 17:17
  Speaker 1: dangerous illusion. We have mapped out the automated post-market surveillance
• 17:21
  Speaker 1: trap of Brazil's Anvisa. Right. We have navigated the paradox
• 17:25
  Speaker 1: of Mexico's COFEPRES, where strict control exists without formal registration.
• 17:30
  Speaker 1: And we have seen how labeling and border logistics physically
• 17:33
  Speaker 1: change the game.
• 17:35
  Speaker 2: It is a lot to navigate.
• 17:37
  Speaker 1: So what does this all mean for the listener trying
• 17:39
  Speaker 1: to build a business here? How do you execute this
• 17:43
  Speaker 1: without maintaining two completely separate product lines?
• 17:46
  Speaker 2: Well, the DDReg industry briefing provides a highly actionable blueprint
• 17:50
  Speaker 2: for a scalable global strategy. Rather than approaching each country
• 17:54
  Speaker 2: from scratch, successful companies utilize a strict two-phase approach.
• 17:58
  Speaker 1: Okay, let's break that down.
• 18:00
  Speaker 2: Phase one focuses on building an immutable, core, standardized foundation.
• 18:05
  Speaker 2: Phase two focuses entirely on local-like tailoring.
• 18:08
  Speaker 1: Let's walk through a hypothetical scenario to see how this
• 18:11
  Speaker 1: two-phase strategy actually operates in the real world.
• 18:14
  Speaker 2: Sure, let's do it.
• 18:16
  Speaker 1: Imagine our listeners' company is manufacturing a premium, high-concentration omega-3
• 18:23
  Speaker 1: fish oil supplement, and they want to launch in both
• 18:25
  Speaker 1: Brazil and Mexico.
• 18:27
  Speaker 2: Good example.
• 18:28
  Speaker 1: Phase one, building the core standardized foundation, sounds like establishing
• 18:32
  Speaker 1: the absolute scientific truth of the product before you ever
• 18:35
  Speaker 1: look at a regulatory map.
• 18:37
  Speaker 2: That is exactly what phase one requires. Good science is universal.
• 18:41
  Speaker 2: A safe, stable product manufactured under pristine conditions is the
• 18:45
  Speaker 2: baseline requirement, whether you are launching in Berlin, Boston, Sao Paulo,
• 18:50
  Speaker 2: or Mexico City.
• 18:52
  Speaker 1: So for this hypothetical omega-3 product, the company locks down
• 18:56
  Speaker 1: their master formula. They standardize their raw material sources, ensuring
• 19:00
  Speaker 1: the fish oil meets universal purity markers for heavy metals
• 19:04
  Speaker 1: and oxidation.
• 19:05
  Speaker 2: Yes, and they compile a comprehensive universal technical dossier. This
• 19:10
  Speaker 2: dossier contains all their peer-reviewed safety literature, rigorous stability studies
• 19:15
  Speaker 2: proving shelf life, and incontrovertible proofs of current good manufacturing practices.
• 19:21
  Speaker 1: So You are essentially building an impenetrable fortress of safety
• 19:25
  Speaker 1: and clinical efficacy. You aren't adjusting the EPA and DHA
• 19:29
  Speaker 1: ratios for different countries. You are declaring, hey, this is
• 19:32
  Speaker 1: our gold standard product.
• 19:33
  Speaker 2: Because altering the core formula for every single market destroys
• 19:37
  Speaker 2: supply chain efficiency and skyrockets manufacturing costs. You lock the
• 19:41
  Speaker 2: core globally, but then you hit phase two, localized tailoring.
• 19:46
  Speaker 2: This is where you run that pristine core foundation through
• 19:49
  Speaker 2: the specificities compliance matrix of your target country.
• 19:52
  Speaker 1: So you split the difference between global manufacturing efficiency and
• 19:56
  Speaker 1: fierce local respect.
• 19:58
  Speaker 2: Exactly.
• 19:58
  Speaker 1: Taking our Omega-3 example, how does phase two differentiate the
• 20:02
  Speaker 1: product for Brazil versus Mexico?
• 20:05
  Speaker 2: In phase two, your regulatory intelligence team takes over. For Brazil,
• 20:09
  Speaker 2: they run the master omega-3 formula against Anvisa's positive lists.
• 20:14
  Speaker 1: Oh, to verify that the specific antioxidant additives used in
• 20:17
  Speaker 1: the fish oil do not exceed Brazil's localized daily caps? Yes.
• 20:21
  Speaker 2: They localize the artwork entirely to Portuguese, ensuring the mandatory
• 20:25
  Speaker 2: suplemento alimentar typography matches Anvisa's specific font size ratios.
• 20:30
  Speaker 1: And they add any mandatory allergy warnings required by the
• 20:33
  Speaker 1: RDC 843 framework. Then they lock in their licensed Brazilian
• 20:37
  Speaker 1: entity to file the automatic notification.
• 20:40
  Speaker 2: Spot on. And then for Mexico, the phase two tailoring
• 20:43
  Speaker 2: completely shifts focus. The core omega-3 oil inside the gel
• 20:47
  Speaker 2: remains identical, but the external presentation adapts to cofibris.
• 20:51
  Speaker 1: So they translate the dossier to Spanish. They painstakingly strip
• 20:55
  Speaker 1: out any marketing phrasing that suggests the omega-3 quote-unquote treats
• 21:00
  Speaker 1: cardiovascular disease. Right.
• 21:02
  Speaker 2: Replacing it with permissible language about augmenting dietary fatty acid intake.
• 21:07
  Speaker 2: They secure their classification consultation, file their establishment notice, and
• 21:11
  Speaker 2: apply for the PSPI using those carefully scrubbed Spanish documents.
• 21:15
  Speaker 1: It makes so much sense. You don't reinvent the wheel
• 21:18
  Speaker 1: every time you cross a border. You centralize the clinical
• 21:21
  Speaker 1: benefits and safety proofs, and you decentralize the regulatory execution.
• 21:26
  Speaker 2: Yes. You leverage specialized local intelligence to shape the final,
• 21:31
  Speaker 2: outward-facing presentation of the product. It allows a company to
• 21:34
  Speaker 2: manufacture at a massive global scale while still clearing highly
• 21:38
  Speaker 2: specific sovereign customs gates with zero friction.
• 21:42
  Speaker 1: It is a brilliant, highly sophisticated framework. To synthesize this
• 21:47
  Speaker 1: vast amount of intelligence for you, the listener, Brazil and
• 21:51
  Speaker 1: Mexico represent absolutely massive, Highly lucrative market opportunities for dietary supplements.
• 21:57
  Speaker 2: Huge opportunities.
• 21:58
  Speaker 1: The consumer demand is surging.
• 22:00
  Speaker 2: Yes. The economic growth is undeniable.
• 22:02
  Speaker 1: But your success hinges entirely on treating them as distinct,
• 22:06
  Speaker 1: sovereign regulatory ecosystems. Implementing a regional commercial strategy for marketing
• 22:11
  Speaker 1: and sales is smart and efficient. But your regulatory execution
• 22:15
  Speaker 1: must remain fiercely, unapologetically country-specific.
• 22:19
  Speaker 2: Absolutely. You just cannot try to use the same key
• 22:21
  Speaker 2: to open two completely different locks.
• 22:24
  Speaker 1: And exploring these two distinct philosophies does raise a deeply
• 22:27
  Speaker 1: provocative question for the future of global regulations.
• 22:30
  Speaker 2: It really does. I mean, we spent time detailing Brazil's
• 22:33
  Speaker 2: model today, that specific automatic notification system backed up by
• 22:38
  Speaker 2: incredibly aggressive real-time post-market surveillance.
• 22:42
  Speaker 1: Like we saw with the turmeric crackdown.
• 22:44
  Speaker 2: Right. So the question is, if that model proves highly successful,
• 22:48
  Speaker 2: keeping consumers safe while drastically reducing the pre-market bureaucratic costs
• 22:52
  Speaker 2: for the Brazilian government... how long will it be until
• 22:56
  Speaker 2: other major global markets adopt it?
• 22:58
  Speaker 1: Oh, wow. A domino effect in global regulatory philosophy. If
• 23:03
  Speaker 1: a government realizes they don't need an army of scientists
• 23:05
  Speaker 1: reviewing dossiers for three years before a vitamin hits the shelf,
• 23:10
  Speaker 1: they might just adopt the automated tollbooth model.
• 23:12
  Speaker 2: Exactly. If global health authorities realize they can shift the
• 23:16
  Speaker 2: burden of proof entirely onto the manufacturer and enforce compliance
• 23:20
  Speaker 2: through real-time data and swift market withdrawals, companies are going
• 23:24
  Speaker 2: to face a massive paradigm shift.
• 23:26
  Speaker 1: Yeah, you will no longer be able to fight for
• 23:28
  Speaker 1: a pre-market approval, get the stamp, and just relax.
• 23:31
  Speaker 2: No. The entire industry will have to rely on continuous,
• 23:35
  Speaker 2: real-time regulatory intelligence just to ensure the product they sold
• 23:39
  Speaker 2: yesterday is still legal to sell tomorrow.
• 23:41
  Speaker 1: The definitive end of the quote-unquote set-it-and-forget-it era of product registration.
• 23:47
  Speaker 1: That is a wildly compelling thought to leave off on,
• 23:49
  Speaker 1: and something you must absolutely factor in as you build
• 23:52
  Speaker 1: out your long-term international expansion plans. Thank you for joining
• 23:56
  Speaker 1: us in the DD Reg Knowledge Capsule today. We hope
• 23:59
  Speaker 1: this deep dive gave you a massive strategic head start
• 24:01
  Speaker 1: on navigating the complexities of the Latin American market. Keep
• 24:05
  Speaker 1: questioning your assumptions, keep demanding the why behind the regulations,
• 24:09
  Speaker 1: and we will catch you on the next deep dive.